Figure 2. Efficacy against P. falciparum Infection.

Shown is the cumulative incidence of the first P. falciparum blood-stage infection during a 6-month malaria season (regardless of the presence of symptoms) after a single subcutaneous injection of 150 mg of L9LS, 300 mg of L9LS, or placebo. P. falciparum infections were detected by means of microscopic examination of thick blood-smear samples obtained during scheduled trial visits and unscheduled visits due to illness. Samples for blood smears were obtained before the administration of L9LS or placebo on day 0 and then on days 3, 7, 14, 21, and 28 and every 2 weeks thereafter, for a total of 24 weeks. Only blood-smear samples that were obtained between week 1 and week 24 were included in the efficacy analysis. Shaded areas indicate 95% confidence intervals.